| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 601.77 | 697.26 |
| Pretax Income | -36.82 | -3.63 |
| Net Income | -19.70 | -150.28 |
| Diluted EPS | -0.25 | -1.94 |
- Net Income YoY
- +86.9%
Key highlights
- Net loss improved by 86.9% year-over-year to $19.70 million compared to $150.28 million in Q3 2025
- Total net revenue declined to $601.77 million from $697.26 million in the prior year period
- Pretax loss widened to $36.82 million from a $3.63 million loss a year ago
- Full-year 2026 revenue guidance was lowered to the bottom of the $2,450 million to $2,550 million range
- A second non-core asset sale part of a $45 million transaction is expected to close by year-end 2026
How the Period Went
Accendra Health experienced a sharp revenue contraction during the third quarter of 2026, with sales falling to $601.77 million from $697.26 million in the same period last year. Despite the lower top-line performance, the company significantly narrowed its net loss to $19.70 million, an 86.9% improvement over the $150.28 million loss reported in the third quarter of 2025. This resulted in a diluted loss per share of $0.25, compared to $1.94 a year ago. However, the operational picture remained pressured as pretax income fell to a loss of $36.82 million, a steep decline from the $3.63 million pretax loss in the prior year.
Margins and Profitability
The company’s profitability profile is heavily influenced by its ongoing restructuring and high accumulated deficit, which reached $568.2 million as of September 30, 2026. Management updated its full-year guidance on November 5, 2026, via Business Wire, indicating that adjusted EBITDA for 2026 is expected to be approximately $217 million. This figure is roughly 30% lower than previous midpoints, reflecting the impact of declining revenues. To stabilize the balance sheet, Accendra is divesting non-core assets. An SEC filing from August confirmed that the sale of a second asset, contributing to a total transaction value of approximately $45 million, is scheduled for completion by December 31, 2026.
Business Overview
Accendra Health operates in the medical distribution industry, serving as a critical link in the healthcare supply chain. The company provides logistics and distribution services for medical supplies to various end markets, including hospitals and clinical facilities across the United States. In the face of recent financial challenges, the company has pivoted toward a leaner operating model by offloading secondary assets. This strategic refocusing is intended to address the company's current micro-cap valuation of approximately $22.9 million and its recent stock price volatility, which has seen the share price trade below $0.30.
Down 71.3% since our story on 6 Nov: $0.30 when we broke it → $0.09 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $0.22 |
|---|---|
| 20 Oct | $0.26 |
| 21 Oct | $0.22 |
| 22 Oct | $0.21 |
| 23 Oct | $0.22 |
| 26 Oct | $0.20 |
| 27 Oct | $0.20 |
| 28 Oct | $0.23 |
| 29 Oct | $0.23 |
| 30 Oct | $0.25 |
| 2 Nov | $0.26 |
| 3 Nov | $0.28 |
| 4 Nov | $0.28 |
| 5 Nov | $0.30 |
| 6 Nov | $0.20 |
| 9 Nov | $0.18 |
| 10 Nov | $0.15 |
| 11 Nov | $0.15 |
| 12 Nov | $0.15 |
| 13 Nov | $0.13 |
| 16 Nov | $0.09 |
Financial Context and Compliance
The third quarter results follow a period of intense market pressure, with Accendra's stock price dropping 89.8% over the last quarter. According to reports from Business Wire, the company received a notice of non-compliance from the NYSE on October 27, 2026, regarding Section 802.01B. Accendra must submit a business plan by December 11, 2026, detailing its strategy to regain listing compliance within an 18-month window. With a Relative Strength Index (RSI) of 35.6, technical indicators suggest the stock is nearing oversold levels, while the company maintains an annual revenue base of $2,762.03 million despite its shrinking market capitalization.
Industry Landscape
- Medical distribution providers are facing increased pressure to optimize logistics as supply chain costs remain elevated.
- Smaller healthcare distributors are increasingly turning to divestitures of non-core assets to maintain liquidity.
- Consolidation among healthcare providers has shifted bargaining power, impacting the margins of independent distributors.
- Market sentiment for micro-cap healthcare stocks remains cautious amid high interest rates and regulatory scrutiny.
- Peer comparisons show a widening gap between large-scale national distributors and specialized regional players.
| Share price | $0.30 |
|---|---|
| Market cap | $23M |
| Revenue (annual) | $2.8B |
| 1-month price change | -36.17% |
| Sector | HealthcareMedical Distribution |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Accendra Health Inc/VA/ announcing its third quarter 2026 financial results.
Track ACCENDRA HEALTH INC/VA/ live
Get the next ACCENDRA HEALTH INC/VA/ SEC filing seconds after it lands.



